These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 17547116)

  • 21. [NSAID-gastropathy: state-of-the-art therapy optimization capabilities in outpatient practice].
    Burkov SG; Arutiunov AT; Gurova NIu; Lobanova EG; Nikiforov PA; Okoemov MN; Cherezova IN; Chugunnikova LI
    Eksp Klin Gastroenterol; 2008; (3):97-101. PubMed ID: 19145889
    [No Abstract]   [Full Text] [Related]  

  • 22. Non-steroidal anti-inflammatory drug gastropathy: clinical results with misoprostol.
    Koch M
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S54-62. PubMed ID: 10379471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effectiveness, safety, and costs of measures for prevention of gastropathy due to the use of nonsteroidal antiinflammatory drugs].
    Steen KS; Lems WF; Dijkmans BA
    Ned Tijdschr Geneeskd; 1999 Aug; 143(32):1649-52. PubMed ID: 10494299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Misoprostol and NSAID ulcers.
    Isaacs P
    Am J Gastroenterol; 1996 Feb; 91(2):187-8. PubMed ID: 8607480
    [No Abstract]   [Full Text] [Related]  

  • 25. Healing and prevention of NSAID-associated ulcer disease: is seeing believing?
    Fendrick AM; Scheiman JM
    Am J Gastroenterol; 1998 Dec; 93(12):2628-9. PubMed ID: 9860450
    [No Abstract]   [Full Text] [Related]  

  • 26. [The use of misoprostol in prevention of gastric disease from nonsteroidal anti-inflammatory drugs in oral-maxillofacial surgery].
    Bocca M; Giordano M; Del Pizzo M; Nelken A; Ghiggia M; Pomatto E
    Minerva Ortognatod; 1990; 8(2):139-41. PubMed ID: 2126183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Combined treatment of gastric ulcers induced by nonsteroid antiinflammatory drugs. Results of 4-week population-based controlled trial of efficacy of proton pump inhibitor combination with tripotassium bismuth dicitrate].
    Karateev AE; Uspenskiĭ IuP; Pakhomova IG; Nasonov EL
    Ter Arkh; 2009; 81(6):62-7. PubMed ID: 19663196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prophylaxis and treatment of NSAID-induced gastropathy.
    Ament PW; Childers RS
    Am Fam Physician; 1997 Mar; 55(4):1323-6, 1331-2. PubMed ID: 9092293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of H2-receptor antagonist and proton pump inhibitor on microbial proliferation in the stomach.
    Wang K; Lin HJ; Perng CL; Tseng GY; Yu KW; Chang FY; Lee SD
    Hepatogastroenterology; 2004; 51(59):1540-3. PubMed ID: 15362796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapy for ulcers and erosions associated with nonsteroidal anti-inflammatory drugs.
    Freeman HJ
    Can J Gastroenterol; 1998; 12(8):537-9. PubMed ID: 10206732
    [No Abstract]   [Full Text] [Related]  

  • 31. [Prevention of NSAID-induced gastric lesions: H2 antagonists or misoprostol? A meta-analysis of controlled clinical studies].
    Capurso L; Koch M
    Clin Ter; 1991 Dec 15-31; 139(5-6):179-89. PubMed ID: 1686995
    [No Abstract]   [Full Text] [Related]  

  • 32. Non-steroidal anti-inflammatory drug gastropathy: clinical results with antacids and sucralfate.
    Lazzaroni M; Sainaghi M; Bianchi Porro G
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S48-53. PubMed ID: 10379470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Role of prostaglandins in the pathogenesis of stomach ulcer and gastropathy caused by non-steroid anti-inflammatory drugs].
    Lazebnik LB; Tkachenko VN; Kolomiets EV
    Eksp Klin Gastroenterol; 2005; (1):4-7, 106. PubMed ID: 15991845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs.
    Ray WA; Chung CP; Stein CM; Smalley WE; Hall K; Arbogast PG; Griffin MR
    Gastroenterology; 2007 Sep; 133(3):790-8. PubMed ID: 17854591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mucosal protective agents prevent exacerbation of NSAID-induced small intestinal lesions caused by antisecretory drugs in rats.
    Satoh H; Amagase K; Takeuchi K
    J Pharmacol Exp Ther; 2014 Feb; 348(2):227-35. PubMed ID: 24254524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention and treatment of nonsteroidal anti-inflammatory drug-induced gastropathy.
    Lee M
    South Med J; 1995 May; 88(5):507-13. PubMed ID: 7732438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Making sense of NSAID gastropathy and considering the therapeutic options.
    Agrawal NM
    Scand J Rheumatol Suppl; 1992; 92():13-9. PubMed ID: 1349444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparative efficacy of different therapeutic schemes in gastropathies induced by nonsteroid anti-inflammatory drugs].
    Maev IV; V'iuchnova ES; Staseva IV
    Ter Arkh; 2004; 76(2):27-30. PubMed ID: 15106410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-ulcer drugs in antisecretory doses for "cytoprotection" in arthritic patients?
    Londong W
    Klin Wochenschr; 1986; 64 Suppl 7():32-4. PubMed ID: 2882050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Role of ranitidine in the treatment and prevention of NSAID-induced digestive lesions].
    Bommelaer G
    Rev Med Suisse Romande; 1995 Oct; 115(10):799-802. PubMed ID: 7501933
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.